Patents by Inventor Jean-François Haeuw
Jean-François Haeuw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130303734Abstract: The present disclosure relates to novel humanized antibodies able to inhibit tumor growth, as well as the amino and nucleic acid sequences coding for such antibodies. From one aspect, the disclosure relates to novel anti-JAM-A homogeneous humanized antibodies able to inhibit tumor growth. The disclosure also comprises the use of such antibodies as a drug for the preventive and/or therapeutic treatment of cancers, as well as compositions comprising such antibodies in combination with other anticancer compounds. The disclosure also relates to a method for the preparation of such novel humanized antibodies.Type: ApplicationFiled: November 23, 2011Publication date: November 14, 2013Applicant: PIERRE FABRE MEDICAMENTInventors: Liliane Goetsch, Nathalie Corvaia, Jean-François Haeuw, Cédric Bes, Alain Beck
-
Publication number: 20120284810Abstract: The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanized, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.Type: ApplicationFiled: April 5, 2012Publication date: November 8, 2012Inventor: Jean-Francois HAEUW
-
Publication number: 20120275997Abstract: The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those anitbodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.Type: ApplicationFiled: October 8, 2010Publication date: November 1, 2012Inventor: Jean-François Haeuw
-
Publication number: 20120219569Abstract: The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the treatment of cancer. The invention is also directed to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CD151 antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and/or of inhibiting the development of primary tumours and/or of inhibiting its metastasis-promoting activity, which antibodies may consist of the antibodies TS151 and/or TS151r.Type: ApplicationFiled: April 16, 2012Publication date: August 30, 2012Applicant: PIERRE FABRE MEDICAMENTInventors: JEAN-FRANÇOIS HAEUW, LILIANE GOETSCH
-
Publication number: 20120208721Abstract: The present invention relates to methods of identifying IGF-IR modulators and hybrid-R modulators comprising contacting IGF-IR with a humanized anti-IGF-IR antibody and contacting hybrid-R with a humanized anti-hybrid-R antibody, respectively.Type: ApplicationFiled: January 18, 2012Publication date: August 16, 2012Applicant: Pierre Fabre MedicamentInventors: Liliane GOETSCH, Nathalie Corvaia, Alain Duflos, Jean-Francois Haeuw, Olivier Leger, Alain Beck
-
Publication number: 20120171114Abstract: The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.Type: ApplicationFiled: November 29, 2011Publication date: July 5, 2012Inventor: Jean-François Haeuw
-
Publication number: 20120156191Abstract: The present invention relates to novel isolated antibodies, derived compounds, and functional isolated antibody fragments, capable of inhibiting the proliferation of tumor cells in vitro and/or in vivo and obtained by functional screening. More particularly, the present invention relates to the 6F4 antibody, specific to the JAM-A protein, as well as its use for the treatment of cancer. Pharmaceutical compositions composed of these antibodies are also covered.Type: ApplicationFiled: December 5, 2011Publication date: June 21, 2012Applicant: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Jean-Francois Haeuw, Cédric Bes
-
Patent number: 8198413Abstract: The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.Type: GrantFiled: October 9, 2009Date of Patent: June 12, 2012Assignee: Pierre Fabre MedicamentInventor: Jean-François Haeuw
-
Patent number: 8178096Abstract: The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumor growth, in the preparation of a medicament intended for the treatment of cancer. The invention is also directed to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CD151 antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and/or of inhibiting the development of primary tumors and/or of inhibiting its metastasis-promoting activity, which antibodies may consist of the antibodies TS151 and/or TS151r.Type: GrantFiled: October 15, 2007Date of Patent: May 15, 2012Assignee: Pierre Fabre MedicamentInventors: Jean-Francois Haeuw, Liliane Goetsch
-
Patent number: 8168410Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.Type: GrantFiled: March 1, 2011Date of Patent: May 1, 2012Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Olivier Leger, Alain Duflos, Jean-François Haeuw, Alain Beck
-
Patent number: 8101180Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR and/or hybrid-R or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or hybrid-R.Type: GrantFiled: February 19, 2009Date of Patent: January 24, 2012Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Alain Duflos, Jean-Francois Haeuw, Olivier Leger, Alain Beck
-
Patent number: 8071730Abstract: The present invention relates to novel isolated antibodies, derived compounds, and functional isolated antibody fragments, capable of inhibiting the proliferation of tumor cells in vitro and/or in vivo and obtained by functional screening. More particularly, the present invention relates to the 6F4 antibody, specific to the JAM-A protein, as well as its use for the treatment of cancer. Pharmaceutical compositions composed of these antibodies are also covered.Type: GrantFiled: May 22, 2008Date of Patent: December 6, 2011Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Jean-François Haeuw, Cédric Bes
-
Publication number: 20110183376Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.Type: ApplicationFiled: March 1, 2011Publication date: July 28, 2011Applicant: PIERRE FABRE MEDICAMENTInventors: Liliane GOETSCH, Nathalie Corvaia, Olivier Leger, Alain Duflos, Jean-François Haeuw, Alain Beck
-
Publication number: 20110165062Abstract: The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the early treatment of cancer. The invention is also directed to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CD151 antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and/or inhibiting its metastasis-promoting activity, said antibodies consisting of antibodies secreted by the hybridoma deposited at the ATCC under number CRL-2696.Type: ApplicationFiled: April 2, 2009Publication date: July 7, 2011Applicant: PIERRE FABRE MEDICAMENTInventor: Jean-Francois Haeuw
-
Patent number: 7914784Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.Type: GrantFiled: April 10, 2007Date of Patent: March 29, 2011Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Olivier Leger, Alain Duflos, Jean-François Haeuw, Alain Beck
-
Publication number: 20110014122Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR and/or hybrid-R or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or hybrid-R.Type: ApplicationFiled: February 19, 2009Publication date: January 20, 2011Applicant: Pierre Fabre MedicamentInventors: Liliane GOETSCH, Nathalie Corvaia, Alain Duflos, Jean-Francois Haeuw, Olivier Leger, Alain Beck
-
Publication number: 20100150902Abstract: The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.Type: ApplicationFiled: October 9, 2009Publication date: June 17, 2010Inventor: Jean-Francois HAEUW
-
Publication number: 20100092455Abstract: The present invention relates to novel isolated antibodies, or the derived compounds or functional fragments of same, capable of inhibiting the proliferation of tumor cells in vitro and/or in vivo, said antibodies having been obtained by functional screening. More particularly, the present invention relates to the 6F4 antibody, specific to the JAM-A protein, as well as its use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies are also covered.Type: ApplicationFiled: May 22, 2008Publication date: April 15, 2010Applicant: PIERRE FABRE MEDICAMENTInventors: Liliane Goetsch, Nathalie Corvaia, Jean-Francois Haeuw, Cedric Bes
-
Publication number: 20090324600Abstract: The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the treatment of cancer. The invention is also directed to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CD151 antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and/or of inhibiting the development of primary tumours and/or of inhibiting its metastasis-promoting activity, which antibodies may consist of the antibodies TS151 and/or TS151r.Type: ApplicationFiled: October 15, 2007Publication date: December 31, 2009Applicant: PIERRE FABRE MEDICAMENTInventors: Jean-Francois Haeuw, Liliane Goetsch
-
Patent number: 7553485Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR and/or hybrid-R or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or hybrid-R.Type: GrantFiled: December 16, 2004Date of Patent: June 30, 2009Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Alain Duflos, Jean-Francois Haeuw, Olivier Leger, Alain Beck